Successful combination of anti-CD33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia

Br J Haematol. 2003 Mar;120(6):1093-4. doi: 10.1046/j.1365-2141.2003.04208_4.x.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • Aminoglycosides*
  • Anti-Bacterial Agents / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Female
  • Gemtuzumab
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Leukemia, Myeloid / drug therapy*
  • Leukemia, Myeloid / surgery
  • Reoperation
  • Transplantation Conditioning*
  • Transplantation, Homologous

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Gemtuzumab